{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:16:29Z","timestamp":1781118989372,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"AGAPE Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40120-026-00906-2","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T10:05:06Z","timestamp":1772964306000},"page":"1099-1120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Comparative Effectiveness Study of Lorazepam or IVIg Versus no Treatment for Down Syndrome Regression Disorder"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8350-8234","authenticated-orcid":false,"given":"Jonathan D.","family":"Santoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Jafarpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panteha Hayati","family":"Rezvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mellad M.","family":"Khoshnood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin N.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Kazerooni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi A.","family":"Spinazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhiben","family":"Anadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen S.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn A.","family":"Filipink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie A.","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen A.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Rafii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,8]]},"reference":[{"issue":"4","key":"906_CR1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/ajmg.a.37001","volume":"167a","author":"G de Graaf","year":"2015","unstructured":"de Graaf G, Buckley F, Skotko BG. Estimates of the live births, natural losses, and elective terminations with Down syndrome in the United States. Am J Med Genet A. 2015;167a(4):756\u201367. https:\/\/doi.org\/10.1002\/ajmg.a.37001.","journal-title":"Am J Med Genet A"},{"issue":"24","key":"906_CR2","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1056\/NEJMra1706537","volume":"382","author":"MJ Bull","year":"2020","unstructured":"Bull MJ. Down Syndrome. N Engl J Med. 2020;382(24):2344\u201352. https:\/\/doi.org\/10.1056\/NEJMra1706537.","journal-title":"N Engl J Med"},{"issue":"2","key":"906_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.17294\/2330-0698.1824","volume":"8","author":"B Chicoine","year":"2021","unstructured":"Chicoine B, Rivelli A, Fitzpatrick V, Chicoine L, Jia G, Rzhetsky A. Prevalence of common disease conditions in a large cohort of individuals with Down syndrome in the United States. J Patient-Cent Res Rev. 2021;8(2):86\u201397. https:\/\/doi.org\/10.17294\/2330-0698.1824.","journal-title":"J Patient-Cent Res Rev"},{"issue":"2","key":"906_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/jir.12804","volume":"65","author":"D Valentini","year":"2021","unstructured":"Valentini D, Di Camillo C, Mirante N, Vallogini G, Olivini N, Baban A, et al. Medical conditions of children and young people with Down syndrome. J Intellect Disabil Res. 2021;65(2):199\u2013209. https:\/\/doi.org\/10.1111\/jir.12804.","journal-title":"J Intellect Disabil Res"},{"key":"906_CR5","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-2939","author":"M Rosso","year":"2020","unstructured":"Rosso M, Fremion E, Santoro SL, Oreskovic NM, Chitnis T, Skotko BG, et al. Down Syndrome Disintegrative Disorder: a clinical regression syndrome of increasing importance. Pediatrics. 2020. https:\/\/doi.org\/10.1542\/peds.2019-2939.","journal-title":"Pediatrics"},{"issue":"9","key":"906_CR6","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1177\/0883073814554654","volume":"30","author":"G Worley","year":"2015","unstructured":"Worley G, Crissman BG, Cadogan E, Milleson C, Adkins DW, Kishnani PS. Down Syndrome Disintegrative Disorder: new-onset autistic regression, dementia, and insomnia in older children and adolescents with Down Syndrome. J Child Neurol. 2015;30(9):1147\u201352. https:\/\/doi.org\/10.1177\/0883073814554654.","journal-title":"J Child Neurol"},{"key":"906_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci7060057","author":"C Mircher","year":"2017","unstructured":"Mircher C, Cieuta-Walti C, Marey I, Rebillat AS, Cretu L, Milenko E, et al. Acute regression in young people with Down syndrome. Brain Sci. 2017. https:\/\/doi.org\/10.3390\/brainsci7060057.","journal-title":"Brain Sci"},{"issue":"4","key":"906_CR8","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/YCT.0b013e31821d37c6","volume":"27","author":"SN Jap","year":"2011","unstructured":"Jap SN, Ghaziuddin N. Catatonia among adolescents with Down syndrome: a review and 2 case reports. J ect. 2011;27(4):334\u20137. https:\/\/doi.org\/10.1097\/YCT.0b013e31821d37c6.","journal-title":"J ect"},{"key":"906_CR9","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2147\/NDT.S77307","volume":"11","author":"N Ghaziuddin","year":"2015","unstructured":"Ghaziuddin N, Nassiri A, Miles JH. Catatonia in Down syndrome; a treatable cause of regression. Neuropsychiatr Dis Treat. 2015;11:941\u20139. https:\/\/doi.org\/10.2147\/NDT.S77307.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"906_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s11689-022-09446-w","volume":"14","author":"JD Santoro","year":"2022","unstructured":"Santoro JD, Partridge R, Tanna R, Pagarkar D, Khoshnood M, Rehmani M, et al. Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder. J Neurodev Disord. 2022;14(1):35. https:\/\/doi.org\/10.1186\/s11689-022-09446-w.","journal-title":"J Neurodev Disord"},{"issue":"4","key":"906_CR11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41436-019-0706-8","volume":"22","author":"SL Santoro","year":"2020","unstructured":"Santoro SL, Cannon S, Capone G, Franklin C, Hart SJ, Hobensack V, et al. Unexplained regression in Down syndrome: 35 cases from an international Down syndrome database. Genet Med. 2020;22(4):767\u201376. https:\/\/doi.org\/10.1038\/s41436-019-0706-8.","journal-title":"Genet Med"},{"key":"906_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.62922","author":"SL Santoro","year":"2022","unstructured":"Santoro SL, Baumer NT, Cornacchia M, Franklin C, Hart SJ, Haugen K, et al. Unexplained regression in Down syndrome: management of 51 patients in an international patient database. Am J Med Genet A. 2022. https:\/\/doi.org\/10.1002\/ajmg.a.62922.","journal-title":"Am J Med Genet A"},{"issue":"10242","key":"906_CR13","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/S0140-6736(20)30689-9","volume":"395","author":"J Fortea","year":"2020","unstructured":"Fortea J, Vilaplana E, Carmona-Iragui M, Benejam B, Videla L, Barroeta I, et al. Clinical and biomarker changes of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study. Lancet. 2020;395(10242):1988\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(20)30689-9.","journal-title":"Lancet"},{"issue":"1","key":"906_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/alz.13444","volume":"20","author":"MD Zammit","year":"2024","unstructured":"Zammit MD, Betthauser TJ, McVea AK, Laymon CM, Tudorascu DL, Johnson SC, et al. Characterizing the emergence of amyloid and tau burden in Down syndrome. Alzheimers Dement. 2024;20(1):388\u201398. https:\/\/doi.org\/10.1002\/alz.13444.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"906_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02579-z","volume":"13","author":"JD Santoro","year":"2023","unstructured":"Santoro JD, Spinazzi NA, Filipink RA, Hayati-Rezvan P, Kammeyer R, Patel L, et al. Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder. Transl Psychiatry. 2023;13(1):276. https:\/\/doi.org\/10.1038\/s41398-023-02579-z.","journal-title":"Transl Psychiatry"},{"key":"906_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52023","author":"JD Santoro","year":"2024","unstructured":"Santoro JD, Khoshnood MM, Jafarpour S, Nguyen L, Boyd NK, Vogel BN, et al. Neuroimaging abnormalities associated with immunotherapy responsiveness in Down syndrome regression disorder. Ann Clin Transl Neurol. 2024. https:\/\/doi.org\/10.1002\/acn3.52023.","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"906_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/dmcn.14127","volume":"61","author":"KM Cardinale","year":"2019","unstructured":"Cardinale KM, Bocharnikov A, Hart SJ, Baker JA, Eckstein C, Jasien JM, et al. Immunotherapy in selected patients with Down syndrome disintegrative disorder. Dev Med Child Neurol. 2019;61(7):847\u201351. https:\/\/doi.org\/10.1111\/dmcn.14127.","journal-title":"Dev Med Child Neurol"},{"key":"906_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.621637","volume":"12","author":"SJ Hart","year":"2021","unstructured":"Hart SJ, Worley G, Kishnani PS, Van Mater H. Case report: improvement following immunotherapy in an individual with seronegative Down syndrome disintegrative disorder. Front Neurol. 2021;12:621637. https:\/\/doi.org\/10.3389\/fneur.2021.621637.","journal-title":"Front Neurol"},{"key":"906_CR19","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.2147\/NDT.S210613","volume":"15","author":"JH Miles","year":"2019","unstructured":"Miles JH, Takahashi N, Muckerman J, Nowell KP, Ithman M. Catatonia in Down syndrome: systematic approach to diagnosis, treatment and outcome assessment based on a case series of seven patients. Neuropsychiatr Dis Treat. 2019;15:2723\u201341. https:\/\/doi.org\/10.2147\/NDT.S210613.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"906_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.940175","volume":"13","author":"JD Santoro","year":"2022","unstructured":"Santoro JD, Patel L, Kammeyer R, Filipink RA, Gombolay GY, Cardinale KM, et al. Assessment and diagnosis of Down syndrome regression disorder: international expert consensus. Front Neurol. 2022;13:940175. https:\/\/doi.org\/10.3389\/fneur.2022.940175.","journal-title":"Front Neurol"},{"issue":"4","key":"906_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/02698811231158232","volume":"37","author":"JP Rogers","year":"2023","unstructured":"Rogers JP, Oldham MA, Fricchione G, Northoff G, Ellen Wilson J, Mann SC, et al. Evidence-based consensus guidelines for the management of catatonia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2023;37(4):327\u201369. https:\/\/doi.org\/10.1177\/02698811231158232.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"906_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/hup.1084","volume":"25","author":"A Richter","year":"2010","unstructured":"Richter A, Grimm S, Northoff G. Lorazepam modulates orbitofrontal signal changes during emotional processing in catatonia. Hum Psychopharmacol Clin Exp. 2010;25(1):55\u201362. https:\/\/doi.org\/10.1002\/hup.1084.","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"7","key":"906_CR23","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","volume":"92","author":"H Abboud","year":"2021","unstructured":"Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. 2021;92(7):757\u201368. https:\/\/doi.org\/10.1136\/jnnp-2020-325300.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"906_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-04505-x","volume":"23","author":"H Wu","year":"2023","unstructured":"Wu H, Wu C, Zhou Y, Huang S, Zhu S. Catatonia in adult anti-NMDAR encephalitis: an observational cohort study. BMC Psychiatry. 2023;23(1):94. https:\/\/doi.org\/10.1186\/s12888-022-04505-x.","journal-title":"BMC Psychiatry"},{"issue":"2","key":"906_CR25","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1097\/YCT.0000000000001093","volume":"41","author":"BJ Kelley","year":"2025","unstructured":"Kelley BJ, Bailey KJ, Hubregsen JJ. Clinical response to electroconvulsive therapy in a young adult with Down syndrome regression disorder. J ect. 2025;41(2):e18\u201320. https:\/\/doi.org\/10.1097\/YCT.0000000000001093.","journal-title":"J ect"},{"issue":"1","key":"906_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-81819-8","volume":"14","author":"JD Santoro","year":"2024","unstructured":"Santoro JD, Jafarpour S, Keehan L, Khoshnood MM, Kazerooni L, Boyd NK, et al. Diagnostic abnormalities, disease severity and immunotherapy responsiveness in individuals with Down syndrome regression disorder. Sci Rep. 2024;14(1):30865. https:\/\/doi.org\/10.1038\/s41598-024-81819-8.","journal-title":"Sci Rep"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00906-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00906-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00906-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:07:42Z","timestamp":1778681262000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00906-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00906-2","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,8]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jonathan D. Santoro has nothing to disclose. Saba Jafarpour has nothing to disclose. Panteha Hayati Rezvan has nothing to disclose. Mellad M. Khoshnood has nothing to disclose. Benjamin N. Vogel has nothing to disclose. Lina Nguyen has nothing to disclose. Lilia Kazerooni has nothing to disclose. Noemi A. Spinazzi has nothing to disclose. Nidhiben Anadani has nothing to disclose. Kristen S. Fisher has nothing to disclose. Robyn A. Filipink has nothing to disclose. Melanie A. Manning has nothing to disclose. Cathy Franklin has nothing to disclose. Eileen A. Quinn has nothing to disclose. Michael S. Rafii has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was approved by the Children\u2019s Hospital Los Angeles (CHLA) institutional review board (IRB) in accordance with the Declaration of Helsinki of 1964. Individuals evaluated for DSRD in clinical care were enrolled into a prospective observational natural history study where these data were systematically tracked and stored in a database. Given that symptoms of DSRD are neurocognitive and neuropsychiatric in nature, informed consent was obtained from parents or guardians in all circumstances as no individual had capacity to consent for this study. Assent was obtained when possible and waived when neurocognitive impairment was too profound for the patient to reasonably assent. Individuals required enrollment at the primary site (CHLA) but could have follow-up at other sites if endpoint measures could be completed in the necessary timeframe.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}